open access

Vol 58, No 3 (2007)
Original papers
Published online: 2007-09-19
Submitted: 2013-02-15
Get Citation

Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations

Michał Rabijewski, Wojciech Zgliczyński
Endokrynologia Polska 2007;58(3):213-219.

open access

Vol 58, No 3 (2007)
Original papers
Published online: 2007-09-19
Submitted: 2013-02-15

Abstract

Introduction: The aim of this study was to analyze the influence of DHEA therapy on fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations in men with decreased serum DHEA-S levels and angiographically verified coronary heart disease (CHD).
Material and methods: The study included thirty men aged 41-60 years (mean age 52 &plusmn; 0.90 yr) with serum DHEA-S concentration < 2000 mg/l, who were randomized into a double-blind, placebo-controlled, cross-over trial. Subjects completed the 80 days study of 40 days of 150 mg oral DHEA daily or placebo, and next groups were changed after 30 days of wash-out. Fasting early morning blood samples were obtained at baseline and after each treatment to determine serum hormones levels (testosterone, DHEA-S, LH, FSH and estradiol) and also fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations.
Results: Administration of DHEA was associated with 4.5-fold increase in DHEA-S levels. Estrogen levels significantly increased after DHEA from 22.1 &plusmn; 0.7 pg/ml to 26.4 &plusmn; 1.6 pg/l (mean &plusmn; SEM; p < 0.05), while testosterone levels did not changed. Fibrinogen concentrations significantly decreased in DHEA group from 4.5 &plusmn; 0.3 g/l to 3.83 &plusmn; 0.2 g/l (p < 0.05 vs. placebo). Changes of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were not statistical significant (respectively: 8.37 &plusmn; 0.4 ng/ml vs. 8.93 &plusmn; 0.5 ng/ml and 82.3 &plusmn; 6.3 ng/ml vs. 92.7 &plusmn; 9.1 ng/ml (mean &plusmn; SEM; NS vs. placebo). Tolerance of the treatment was good and no adverse effects were observed.
Conclusions: DHEA therapy in dose of 150 mg daily during 40 days in men with DHEAS levels < 2000 mg/l and angiographically verified coronary heart disease (CHD) was connected with significant decreasing of fibrinogen concentration and increasing of estradiol levels, and did not influence on plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations. (Pol J Endocrinol 2007; 58 (3): 213-219)

Abstract

Introduction: The aim of this study was to analyze the influence of DHEA therapy on fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations in men with decreased serum DHEA-S levels and angiographically verified coronary heart disease (CHD).
Material and methods: The study included thirty men aged 41-60 years (mean age 52 &plusmn; 0.90 yr) with serum DHEA-S concentration < 2000 mg/l, who were randomized into a double-blind, placebo-controlled, cross-over trial. Subjects completed the 80 days study of 40 days of 150 mg oral DHEA daily or placebo, and next groups were changed after 30 days of wash-out. Fasting early morning blood samples were obtained at baseline and after each treatment to determine serum hormones levels (testosterone, DHEA-S, LH, FSH and estradiol) and also fibrinogen, plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations.
Results: Administration of DHEA was associated with 4.5-fold increase in DHEA-S levels. Estrogen levels significantly increased after DHEA from 22.1 &plusmn; 0.7 pg/ml to 26.4 &plusmn; 1.6 pg/l (mean &plusmn; SEM; p < 0.05), while testosterone levels did not changed. Fibrinogen concentrations significantly decreased in DHEA group from 4.5 &plusmn; 0.3 g/l to 3.83 &plusmn; 0.2 g/l (p < 0.05 vs. placebo). Changes of tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) were not statistical significant (respectively: 8.37 &plusmn; 0.4 ng/ml vs. 8.93 &plusmn; 0.5 ng/ml and 82.3 &plusmn; 6.3 ng/ml vs. 92.7 &plusmn; 9.1 ng/ml (mean &plusmn; SEM; NS vs. placebo). Tolerance of the treatment was good and no adverse effects were observed.
Conclusions: DHEA therapy in dose of 150 mg daily during 40 days in men with DHEAS levels < 2000 mg/l and angiographically verified coronary heart disease (CHD) was connected with significant decreasing of fibrinogen concentration and increasing of estradiol levels, and did not influence on plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (tPA) plasma concentrations. (Pol J Endocrinol 2007; 58 (3): 213-219)
Get Citation

Keywords

DHEA therapy; men; fibrinogen; plasminogen activator inhibitor-1 (PAI-1); tissue plasminogen activator (tPA); coronary heart disease

About this article
Title

Dehydroepiandrosterone therapy in men with angiographically verified coronary heart disease: the effects on plasminogen activator inhibitor-1 (PAI-1), tissue plasminogen activator (tPA) and fibrinogen plasma concentrations

Journal

Endokrynologia Polska

Issue

Vol 58, No 3 (2007)

Pages

213-219

Published online

2007-09-19

Bibliographic record

Endokrynologia Polska 2007;58(3):213-219.

Keywords

DHEA therapy
men
fibrinogen
plasminogen activator inhibitor-1 (PAI-1)
tissue plasminogen activator (tPA)
coronary heart disease

Authors

Michał Rabijewski
Wojciech Zgliczyński

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl